MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.cyto.2023.156433

Медицинская библиотека · Cytokine · 2023

Even one dose of tocilizumab could hinder bad prognosis of cytokines storm in COVID-19 patients.

Abdel-Salam Elgohary Mohamed, Ali Asmaa, J Alarfaj Sumaiah, Shahin Hesham, Ibrahim Zaki Ashraf, Medhat Hasan Eman, Emam Mohamed Mohamed, Mahmoud Elkholy Ahmad, El-Masry Thanaa A, Samir Kamal Jacklin, Ali AbdelRahim Mohammed, Wageh Saber Ashgan, Seadawy Mohamed G, Elshishtawy Mohamed H M, El-Bouseary Maisra M

СтатьяПеревод в очереди

Аннотация

Severe COVID-19 pneumonia is a principal cause of death due to cascade of hyper inflammatory condition that leading to lung damage. Therefore, an effective therapy to countercurrent the surge of uncontrolled inflammation is mandatory to propose. Anti-interlukin-6 receptor antagonist monoclonal therapy, tocilizumab (TCZ) showed potential results in COVID-19 patients. This study aimed to emphasize the factors associated with mortality in COVID-19 patients that treated with tocilizumab and may influence the level of serum IL-6. A retrospective cohort study included all patients with clinical parameters that pointed to presence of cytokines storm and treated with one or more doses of TCZ beside the regular protocol of COVID-19 pneumonia. The factors that influence the mortality in addition to the level of serum IL-6 were analyzed. A total of 377 patients were included, 69.5 % of them received only one dose of TCZ which started mainly at the third day of admission. The mortality rate was 29.44 %. Regardless the time of starting TCZ, just one dose was fair enough to prevent bad consequence; OR = 0.04, P = 0.001.However, in spite of protective action of TCZ, older age and female sex were significant risk factors for mortality, P = 0.001 and 0.01 respectively, as well heart disease. Moreover, increasing the level of neutrophil, AST and IL-6 were associated with bad prognosis. In the same line, treatment with ivermectin, chloroquine and remdesivir inversely affect the level of IL-6. Early treatments of COVID-19 pneumonia with at least one dose of tocilizumab minimized the fatality rate.

Для цитирования: Abdel-Salam Elgohary Mohamed, Ali Asmaa, J Alarfaj Sumaiah, Shahin Hesham, Ibrahim Zaki Ashraf, Medhat Hasan Eman, Emam Mohamed Mohamed, Mahmoud Elkholy Ahmad, El-Masry Thanaa A, Samir Kamal Jacklin, Ali AbdelRahim Mohammed, Wageh Saber Ashgan, Seadawy Mohamed G, Elshishtawy Mohamed H M, El-Bouseary Maisra M. Even one dose of tocilizumab could hinder bad prognosis of cytokines storm in COVID-19 patients.. Cytokine. 2023. DOI: 10.1016/j.cyto.2023.156433.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.